To mark World Glaucoma Week, Medtech Insight takes a look back at some of the innovators in the field that caught investors' interest over the past five years to see how these businesses are doing in their fight against this disease.
Glaucoma is the second-leading cause of blindness worldwide. World Glaucoma Week, March 11-18, was created to raise awareness of this disease, known as "the silent thief."
The incidence of glaucoma is expected to rise to 76 million people by 2020 and 112 million people by 2040...
Allen Burton, Abbott’s medical director of neuromodulation told Medtech Insight that the delivery system was developed to make the procedure easier for physicians, especially those who perform the implantations infrequently.
In this week's Digital Health Roundup, MedTech Insight's Shubham Singh explores how Ketryx's launch of validated AI agents could reshape compliance automation in medtech. Marion Webb highlights news from BCI makers Synchron, Axoft and Subsense. Elizabeth Orr discusses AI advances at the FDA.
Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.
